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Abstract. We explored the association of type 2 diabetes related blood markers with brain amyloid accumulation on PiB-PET
scans in 41 participants from the FINGER PET sub-study. We built logistic regression models for brain amyloid status with12
plasma markers of glucose and lipid metabolism, controlled for diabetes and APOE 4 carrier status. Lower levels of insulin,
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status, although the results were not significant after adjusting for multiple testing. None of the models found evidence for
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INTRODUCTION
The association of type 2 diabetes (DM2) and
insulin resistance (IR) with formation of amyloid-
plaques in Alzheimer’s disease (AD) is still unclear.
DM2 is a risk factor for cognitive impairment and for
the clinical diagnosis of probable AD dementia [1].
However, autopsy studies have consistently found
that DM2 diagnosis is associated with small vessel
pathology and not with AD pathological hallmarks
(amyloid- plaques and neurofibrillary tangles) [2,
3]. IR, an indicator of a pre-diabetic state and a hall-
mark of DM2, has been associated with amyloid
accumulation in middle-aged [4] and late-middle-
aged [5], but not in older [6] cognitively healthy
individuals. A study of older individuals reported no
relation of lifelong IR exposure with either in vivo
or postmortem measures of brain amyloid pathology
[7]. The mechanisms linking amyloid- accumula-
tion and insulin resistance are unclear, and hypotheses
include, e.g., dysregulated hormonal signaling and
“type 3 diabetes” of the brain [8]. We explored
the association of peripheral blood markers of IR
and DM2 with amyloid- accumulation on PET
scans in older individuals at risk for dementia, but
without dementia or substantial cognitive decline.
Our hypothesis was that we would find associations
between exploratory diabetes blood markers and an
amyloid positive status in PET.
METHODS
The study population included 41 participants
in the Finnish Geriatric Intervention Study to Pre-
vent Cognitive Impairment and Disability (FINGER)
exploratory PET sub-study who had available data
on IR and DM2-related blood markers (fasting blood
glucose, insulin, HbA1c, and a 12-itemBio-Plex Pro
Human Diabetes assay). The FINGER main study
[9] and PET sub-study [10] have previously been
described in detail. Briefly, FINGER investigated the
cognitive benefits of a 2-year multi domain lifestyle
intervention versus regular health advice in 1,260
individuals aged 60–77 years from the general popu-
lation. Inclusion criteria were elevated dementia risk
based on Cardiovascular Risk Factors, Aging and
Dementia (CAIDE) score [11], and cognitive perfor-
mance at mean level or slightly lower than expected
for age according to Finnish population norms for the
Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) test. 11C-Pittsburgh compound
B (PiB) PET scans were conducted at the Turku
PET Centre. MR-based attenuation corrected images
with summated PET data over 60–90 min were visu-
ally assessed as amyloid- positive or negative by
two-party consensus agreement. Positive individuals
showed cortical accumulation in at least one AD-
typical region, and negative individuals showed only
nonspecific retention in white matter [10]. The FIN-
GER study was approved by the Coordinating Ethics
Committee of the Hospital District of Helsinki and
Uusimaa. All participants gave written informed con-
sent at the screening and baseline visits, and for the
exploratory neuroimaging sub-study.
In the FINGER study, venous blood samples
were taken at baseline in fasting status and using
EDTA tubes. Plasma aliquots were stored at –80◦C
until analysis. Twelve markers related to glu-
cose and lipid metabolism were analyzed using
the multiplex suspension array system Bio-Plex
Luminex® 200 instrument, (Bio-Rad Laboratories,
Hercules, CA, USA), with the Bio-Plex Pro Human
Diabetes 10-plex panel (C-peptide; ghrelin; GIP, gas-
tric inhibitory polypeptide; GLP-1, glucagon-like
peptide-1; glucagon; insulin; leptin; PAI-1; resistin;
visfatin) and 2-plex panel (adiponectin, adipsin) (Bio-
Rad Laboratories, Hercules, CA, USA). The assays
were performed in one batch, and samples prepa-
ration and setting of the system running protocol
were done following the manufacturer’s instructions
(www.Biorad.com).
In brief, plasma samples (10l) were first diluted
(1 : 400 for adipsin adiponectin; 1 : 4 for all the other
compounds) using Serum Based Diluent provided by
the manufacturer. Assay beads (50l) were trans-
ferred in the 96-well plates and washed twice with
wash buffer. Then, standards and plasma samples
(50l) were added to the appropriate wells. Plates
were incubated for 1 h in a dark room, with mild
agitation at room temperature. The fluid was then
removed by vacuum and wells were washed three
times with wash buffer. Detection antibodies (25l)
were added to each well, and plates were incubated
for 30 min in a dark room, with mild agitation at room
temperature. The fluorescent conjugate Streptavidin-
Phycoerythrin (60l) was then added to each well
and plates incubated for 10 min at room tempera-
ture. Finally, plates were washed with wash buffer
and assay beads were resuspended in assay buffer
(125l in each well), and plate reading was done
with the Bio-Plex Luminex® 200 instrument.
All samples and standards were run in duplicate
and were measured as pg/ml. Quality controls were
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performed according to the manufacturer guidelines
to ensure accuracy of measurements. The intra-assay
coefficient of variability (CV) for all compounds
ranged from 1 to 2%. The detection limits (in pg/ml)
were the following: 32.7 for Adiponectin; 17 for
Adipsin; 14.5 for C-peptide; 1.2 for ghrelin; 0.8 for
GIP; 5.3 for GLP-1; 4.9 for glucagon; 1 for insulin;
3.1 for leptin; 2.2 for PAI-1; 1.3 for resistin; 37.1 for
visfatin). All sample results below the lower limit of
quantitation were classified as missing data.
After the plate reading, the results files were gen-
erated using Bio-Plex Manager software 4 (Bio-Rad
Laboratories, Hercules, CA, USA).
Data from the FINGER baseline visit, before the
start of the intervention, was used in this study. Dia-
betes diagnoses were self-reported at the screening
visit interview with the study physician. The home-
ostatic model assessment of insulin resistance index
(HOMA-IR) was calculated based on fasting blood
insulin and glucose measures. APOE genotype was
determined as described previously [12]. We built a
logistic regression model for brain amyloid- sta-
tus based on log-transformed diabetes markers, and
diabetes status (yes/no) and APOE 4 carrier status
(yes/no) as confounders. Goodness of model fit was
assessed by calculating the percentage of deviance
of the fit explained. We corrected for multiple com-
parisons using the false discovery rate (FDR) method
[13]. All analyses were performed using MATLAB
R2017b (function mnrfit).
RESULTS
The participants’ mean age (SD) was 71.1 (5.0)
years, 51% were female, 15% had diabetes, 29%
were APOE 4 carriers, and 39% had amyloid posi-
tive PiB-PET scans. All participants diagnosed with
diabetes were receiving treatment: five were using
oral glucose-lowering medication and one was using
a combination of oral glucose-lowering medication
and insulin. The individual receiving combination
therapy was amyloid negative. Amyloid-prevalence
was 37% in non-diabetics and 50% in diabetics (p-
value for difference 0.57). APOE4 prevalence was
31% in non-diabetics and 17% in diabetics (p-value
0.48). One person with diabetes had a history of
stroke (amyloid positive), and another person with
diabetes had a history of myocardial infarction (amy-
loid negative).
Table 1 summarizes population characteristics by
amyloid- status. APOE 4 prevalence was signif-
icantly higher in the amyloid positive group (56%
versus 12%, p = 0.003). No statistically significant
differences in age, sex, body mass index (BMI),
diabetes status, or history of stroke or myocar-
dial infarction were observed. IR and DM2-related
markers by amyloid- status are shown in Table 2.
Insulin and plasminogen activator inhibitor-1 (PAI-1)
concentrations were significantly lower in amy-
loid positive compared with negative individuals
(p < 0.05). C-peptide and HOMA-IRwere also lower
in the amyloid positive groups, but differences were
significant only at the 90% confidence level. Other
markers showed no significant between-group differ-
ences.
In the logistic regression model adjusted for dia-
betes status and APOE genotype (Table 2), higher
levels of insulin, HOMA-IR, C-peptide, and PAI-
1were significantly associated with lower odds of
amyloid positivity. After FDR correction, these four
markers were significant only at the 90% confi-
dence level. Models with either BMI, age, or sex
as additional confounders showed a similar pattern,
including after FDR correction. Goodness of fit of
the LR model was also highest for models including
insulin, HOMA-IR, C-peptide, and PAI-1. Fit was
worse in all cases when APOE was removed from
the model.
A further exploratory model was built to assess
the joint effect of PAI-1 and IR related markers.
Table 1




Sex (% female) 52% 50% 0.914
APOE 4 carrier (%) 12% 56% 0.003
Age 70.2 (5.6) 72.4 (3.0) 0.234
BMI 28.1 (3.8) 26.1 (2.8) 0.080
Diabetic (%) 12% 19% 0.570
History of stroke (%) 12% 6% 1.000
History of myocardial infarction (%) 8% 13% 0.637
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Table 2
Associations of IR and DM2-related markers with amyloid status
Mean concentration (SD) Logistic regression model
Amyloid Amyloid pa Bb Adjusted Goodness of fitc
Metabolic marker negative positive (95% confidence interval) p p with APOE without APOE
C-Peptide (103 pg/ml) 1.31 (0.61) 0.95 (0.45) 0.056 -5.70 (-10.35 – -1.05) 0.016 0.072 33.4 % 9.8 %
Ghrelin (103 pg/ml) 1.57 (0.51) 1.55 (0.39) 0.936 0.11 (-6.07 – 6.29) 0.972 0.998 19.0 % 0.6 %
GIP (103 pg/ml) 0.29 (0.12) 0.29 (0.16) 0.479 -1.53 (-5.39 – 2.32) 0.436 0.689 20.1 % 1.4 %
GLP-1 (103 pg/ml) 0.59 (0.11) 0.58 (0.08) 0.224 0.01 (-8.79 – 8.81) 0.998 0.998 19.0 % 0.7 %
Glucagon (103 pg/ml) 1.07 (0.23) 1.00 (0.17) 0.530 -2.14 (-11.30 – 7.01) 0.646 0.808 19.4 % 2.8 %
Insulin (103 pg/ml) 0.27 (0.17) 0.17 (0.09) 0.036 -4.54 (-8.26 – -0.81) 0.017 0.072 33.2 % 13.8 %
Leptin (103 pg/ml) 7.55 (4.79) 6.06 (5.15) 0.145 -1.63 (-4.07 – 0.81) 0.191 0.569 22.2 % 3.6 %
PAI-1 (103 pg/ml) 5.31 (1.32) 4.16 (0.62) 0.003 -13.27 (-23.93 – -2.61) 0.015 0.072 36.0 % 20.0 %
Resistin (103 pg/ml) 2.22 (0.56) 2.03 (0.46) 0.316 -3.67 (-10.13 – 2.79) 0.266 0.569 21.3 % 2.2 %
Visfatin (103 pg/ml) 4.83 (2.25) 4.43 (2.30) 0.224 -2.03 (-6.77 – 2.71) 0.401 0.689 20.3 % 2.8 %
Adiponectin (106 pg/ml) 5.45 (3.44) 6.03 (3.82) 0.548 -0.25 (-2.30 – 1.79) 0.808 0.932 19.1 % 1.2 %
Adipsin (106 pg/ml) 1.21 (0.46) 1.45 (0.89) 0.925 1.08 (-2.06 – 4.22) 0.500 0.689 20.1 % 2.1 %
fP-Glucose (mmol/l) 5.92 (0.88) 6.30 (1.17) 0.303 4.80 (-9.33 – 18.93) 0.505 0.689 19.8 % 2.4 %
B-HbA1c (mmol/mol) 36.72 (4.11) 37.25 (4.63) 0.957 14.96 (-10.94 – 40.86) 0.258 0.569 21.4 % 0.7 %
HOMA-IR (mmol·mU/l²) 2.06 (1.24) 1.33 (0.71) 0.060 -4.52 (-8.31 – -0.74) 0.019 0.072 32.4 % 11.9 %
Regression model: ln (YA+/YA−) = C + BDM · XDM + BAPOE · XAPOE + B · log(X). aSignificance tested using the Mann-Whitney U test.
bCoefficient of log-transformed values. cGoodness of fit expressed in percentage of deviance explained. fP-Glucose, fasting plasma glucose;
GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide-1; PAI-1, plasminogen activator inhibitor-1; B-HbA1c, blood glycated
hemoglobin.
With DM status, APOE, and PAI-1 as confounders,
p-values were insignificant for insulin, HOMA-IR,
C-peptide, fasting glucose, and HbA1c. The coeffi-
cient of PAI-1 was insignificant in models including
insulin, HOMA-IR, and C-peptide, and significant for
fasting glucose, HbA1c, and all other tested analytes.
DISCUSSION
Results from the FINGER PET exploratory sub-
study suggested slightly better insulin homeostasis
and related markers in amyloid positive older indi-
viduals at risk for dementia, but without dementia or
substantial cognitive impairment. Although DM2 has
been indicated as a risk factor for dementia and AD
[1], it is not fully clear whether the underlying mech-
anisms are amyloid-related. Peripheral IR has been
linked to IR in the brain, which may affect amyloid-
pathology through e.g. neuroinflammatory pathways
or competitive cleavage of insulin and amyloid-
by the same enzyme [8]. However, previous stud-
ies investigating peripheral IR and brain amyloid-
in CSFor on PET scans in cognitively healthy indi-
viduals have reported no associations at older ages,
and mixed findings in middle-aged populations [4–6,
14]. Ekblad et al. [4] found that midlife HOMA-IR,
taken 15 years previous to the PET -scan, associ-
ated with greater brain amyloid- accumulation in
elderly individuals without dementia, in both carriers
and noncarriers of APOE 4 genotype, but the same
association was not detected at the time of the scan
in late-life. No associations have also been reported
in people with mild cognitive impairment or AD [6].
Our results contrast with earlier no-association
findings in the elderly, possibly due to the specific
risk profile of the FINGER population. Periph-
eral IR and DM2 may also contribute to cognitive
decline via vascular-related mechanisms. Interest-
ingly, an autopsy study in the 85+ age group showed
less amyloid- pathology and more cerebrovascular
pathology in people with diabetes, who also had an
increased risk of AD dementia [15]. It was suggested
that, in people with diabetes and vascular pathol-
ogy, less amyloid- pathology may be needed to
trigger the onset of dementia. FINGER study partici-
pants had cognitive performance at the mean level or
slightly lower than expected for age, and they were
also at risk for dementia based on the CAIDE score
including age, sex, education, BMI, systolic blood
pressure, total cholesterol, and physical activity [11].
The cognitive performance of a participant could be
hypothesized to be determined by a similar inter-
play of amyloid-- and vascular-related mechanisms,
e.g., poorer insulin homeostasis and higher vascular-
related risk in amyloid negative individuals. It is also
possible that FINGER participants with lower IR rep-
resent a selected group that has maintained better
insulin homeostasis despite elevated cardiovascular
risk. The mechanisms linking IR and amyloid- accu-
mulation may be different in this specific group.
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To our knowledge, this is the first study investigat-
ing the association of peripheral blood PAI-1 level
and invivo brain amyloid-markers. Higher PAI-1
level seemed to be protective against amyloid- accu-
mulation, although not significantly after correction
for multiple comparisons. The effect was not seen in
models including both PAI-1 and IR-related mark-
ers. PAI-1 in CSF has in prior studies been reported
to have no association with AD status [16, 17]. PAI-1
down regulates the activity of the protein-cleaving
plasmin system, and it is considered a risk factor
for atherosclerosis due to its prothrombotic effect. In
the population-based Framingham Offspring Study,
higher fasting insulin level was associated, among
other things, with increased PAI-1 levels [18]. In the
brain, however, PAI-1 and the plasmin system may
interact with amyloid- fibrils and possibly affect
plaque formation [19], or be directly neuroprotec-
tive [20]. A previous study showed that increases
in blood levels of PAI-1 were associated with white
matter integrity loss in stroke-free, cognitively nor-
mal individuals aged 50–65 years and also reported
an association of PAI-1 with lower performance in
speed or visuomotor coordination [21]. It is unclear
if the association suggested in the present study was
mediated through effects in the brain, or if amyloid-
load was reduced due to effects in the cardiovascular
system.
The main strength of this study is the assessment
of a comprehensive assay of IR and DM2-related
markers in relation to brain amyloid- accumula-
tion on PiB-PET, which has not been previously
done. However, the small sample size is a key lim-
itation, restricting statistical power and the ability
to control for other potentially confounding factors.
Additionally, overall amyloid- status was deter-
mined visually from scans, and no region-specific
analyses were conducted. Our exploratory study adds
to the growing amount of data on the associations
of IR and DM2-related markers with AD-related
pathology. Future studies in larger populations and
with longitudinal data should further investigate these
associations, taking into account, e.g., APOE geno-
type, degree of vascular pathology, type of DM2
treatment, and level of glycemic control.
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